Drug Discovery World

MAY 5, 2023

The acquisition will provide Eterna with a pipeline of allogeneic immuno-oncology products under development for the treatment of haematologic and solid tumours. In contrast to DNA-based reprogramming and gene editing, the mRNA-based approach does not expose cells to expensive and potentially harmful viruses or DNA vectors.

Gene Editing 52

Gene Editing Engineer DNA Life Science 52

Pharmaceutical Technology

FEBRUARY 15, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. CRISPR nucleases serve as an important genome editing tool.

In-Vivo 162

In-Vivo Genome Genomics Gene Editing 162

XTalks

NOVEMBER 28, 2023

Indicated for the treatment of trichomoniasis in adults, amebiasis in both adults and pediatric patients and anaerobic bacterial infections in adults, Likmez is available as an oral suspension, with each 5 mL containing 500 mg of metronidazole.

FDA Approval 103

FDA Approval Bacteria DNA Drugs 103

Drug Discovery World

MARCH 26, 2024

DDW’s Megan Thomas caught up with Oliver Rausch, Chief Scientific Officer at Storm Therapeutics, following the ESMO Targeted Anticancer Therapies Congress 2024, a global meeting focusing on promising new anticancer targets and agents, focusing on those in early phase clinical development. MT: What’s next for STORM’s research?

RNA 64

RNA In-Vivo In-Vitro DNA 64

The Pharma Data

DECEMBER 23, 2020

” Dr. Stanley Plotkin , Professor Emeritus at The Wistar Institute, said, “INOVIO’s DNA vaccine appeared to be quite safe with few significant reactions but yet induced both antibody and T cell responses to SARS-CoV-2.” About INOVIO’s DNA Medicines Platform. mg and 2.0

DNA 40

DNA Vaccination Vaccine Immune Response 40

Pharmaceutical Technology

FEBRUARY 15, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. The vaccine also contains other inactive ingredients such as cholesterol.

Vaccination 130

Vaccination Vaccine Containment Immune Response 130

Drug Discovery World

DECEMBER 20, 2023

Using a novel approach, researchers from The Institute of Cancer Research, London have uncovered details of secondary breast cancer in the brain and spinal cord that may help with developing effective treatments.

Drugs 105

Drugs Genetics Research DNA 105

Drug Discovery World

DECEMBER 14, 2023

The Bio X AI policy recommendations address the need for oversight of biodesign AI tools, biosecurity screening of synthetic DNA and guidance on biosecurity practices for automated laboratories. However, AI tools, if misused or developed irresponsibly, can also pose risks to biosecurity.

Scientist 52

Scientist DNA Life Science Development 52

Scienmag

OCTOBER 7, 2020

Computational algorithms enable identification and optimization of RNA-based tools for myriad applications DNA and RNA have been compared to “instruction manuals” containing the information needed for living “machines” to operate.

RNA 69

RNA DNA Containment Bioinformatics 69

The Pharma Data

SEPTEMBER 11, 2021

Boehringer Ingelheim believes Twist’s ability to generate potent, diverse therapeutic antibodies by mining its comprehensive libraries, combined with our extensive capabilities and experience in drug discovery and development, will enable us to deliver breakthrough opportunities to patients,” said Clive R. Wood, Ph.D., Leproust, Ph.D.,

Antibody 52

Antibody DNA Containment Manufacturing 52

Drug Discovery World

AUGUST 14, 2023

Over the past few decades, the incredible progress in personalised medicine has led to the development of life-saving cell and gene therapies (CGT). The agencies also have different requirements for the selection of healthy donors in the development of allogeneic cell therapies. By 2030, it’s expected to more than double, to $34.3

Gene Therapy 52

Gene Therapy Marketing Gene DNA 52

pharmaphorum

AUGUST 5, 2021

The issue, however, is developing an effective way of targeting them. . Critical cellular processes including DNA replication and translation cannot occur without functional-specific proteins. Understanding the mechanism of PPIs and developing methods to target aberrant ones has been a key strategy in drug development.

Protein 126

Protein Gene Bioassay DNA 126

Drug Discovery World

DECEMBER 5, 2022

Scientists have unlocked key insights into virus evolution, revealing new information that could help develop treatments for a wide variety of genetic diseases. . In the study, researchers used ‘fossilised’ virus DNA sequences contained within animal genomes to reconstruct the long-term evolutionary history of parvoviruses.

Gene Therapy 52

Gene Therapy Gene Genetic Disease Genetics 52

Pharma Packaging Solutions

SEPTEMBER 22, 2023

There are a few common types of biologics, including extracted (taken directly from a living system), semi-synthesized (produced with recombinant DNA technology), vaccines, and gene therapies. Because biosimilars have a more streamlined development process than biologics, they are typically more affordable. What are Biosimilars?

Recombinant DNA Technology 52

Recombinant DNA Technology Packaging Packaging Pharma Packaging 52

XTalks

NOVEMBER 6, 2020

Canadian clinical-stage biotech company Symvivo Corporation has developed an oral COVID-19 vaccine that entered clinical trials this week. Graves explained the gene therapy platform delivers plasmid DNA that enables a patient’s own cells to produce therapeutic proteins that work to clear harmful virus particles from healthy tissues.

Clinical Trials 75

Clinical Trials Clinical Trials Vaccination Vaccine 75

FDA Law Blog

MARCH 5, 2024

We will continue to monitor this bill and the legislative, administrative, and judicial developments with respect to this rapidly evolving issue. Spoiler alert: the FAIR on Labels Act brings the traditional and alternative protein industries no closer to “meating” in the middle.

Protein 59

Protein Production DNA Containment 59

Pharmaceutical Technology

MAY 24, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. Amgen is headquartered in Thousand Oaks, California, US.

Protein 130

Protein Antibody Medicine Development 130

pharmaphorum

OCTOBER 19, 2022

The dark genome – a loose term that covers non-coding regions of the genome that are capable of regulating the expression of genes, previously rather inaccurately referred to as junk DNA – is increasingly being explored by biopharma companies for new drug targets. Dr Danuta Jeziorska.

Genome 58

Genome Genomics Gene Gene Expression 58

pharmaphorum

MAY 11, 2021

Laronde thinks that its new class of RNA – a transcript of DNA that can be read by the body and turned into proteins – will cut the number of injections required as the body will actively make the disease-fighting protein instead of passively requiring top-ups.

RNA 98

RNA Drugs Protein Immune Response 98

Worldwide Clinical Trials

JUNE 15, 2022

At the end of May, we hosted a webinar titled “ Changing Times, Changing Therapies: Keeping Up with Advancements in Cell and Gene Therapies ” to provide a quick update on the latest advancements and ongoing in development of these advanced therapeutics. Clinical holds are becoming more common, especially in gene therapy programs.

Gene Therapy 130

Gene Therapy Gene Clinical Trials Clinical Trials 130

Roots Analysis

OCTOBER 16, 2023

DNA cloning refers to the process of generating multiple copies of a particular DNA segment. DNA and Gene Cloning involves the isolation of a DNA sequence of any species ( often a gene ) and its insertion into a vector to enable growth without any alteration in the original DNA sequence.

DNA 40

DNA Gene Protein In-Vitro 40

Roots Analysis

MARCH 8, 2023

INTRODUCTION TO EXOSOMES Exosomes are extracellular vesicles, which have endosomal origin and may contain different biomolecules, including proteins, DNA, lipids, miRNA or RNA , based on the type of cell of their origin and its conditions. As a result, exosome therapeutics domain has been gaining traction recently.

RNA 52

RNA Drug Delivery DNA Development 52

Pharmaceutical Technology

MAY 15, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. Its primary focus is on oncology, cardiovascular, immunology, and fibrotic therapeutic projects.

Antibody 130

Antibody DNA Genome Genomics 130

The Pharma Data

DECEMBER 2, 2020

This press release contains forward-looking statements. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Containment 52

Containment DNA Sales Antibody 52

The Pharma Data

MARCH 30, 2021

Expands Novartis Oncology radioligand pipeline with exclusive worldwide rights to develop and commercialize therapeutic applications for a library of FAP assets including FAPI-46 and FAPI-74. Novartis Oncology continues to reimagine cancer care through development of robust radioligand therapy portfolio. Disclaimer.

Protein 52

Protein Licensing Licensing Containment 52

Delveinsight

JULY 26, 2021

Often the bacteria develop antibiotic resistance to certain drugs, leaving it non-effective for the usage the second time in the case of recurrence of the infection that occurs in approximately 30-35% of the uUTI cases, therefore, leaving a serious dearth of the new antibiotics. The drug is in the development stage of Phase I clinical trial.

Marketing 93

Marketing Bacteria Vaccination Vaccine 93

Roots Analysis

AUGUST 15, 2023

Additionally, these types of cell free systems do not contain proteases and nucleases as crude cell lysates, which further helps in improving the production of many proteins. It is worth mentioning that the first reconstituted system, Protein Synthesis Using Recombinant Elements (PURE) , was developed in 2001.

Protein 52

Protein In-Vitro Production Reagent 52

The Pharma Data

MARCH 7, 2022

Today’s decision underscores our commitment to using a risk and science-based, data-driven process that focuses on safety to the animals containing intentional genomic alterations and safety to the people who eat the food produced by these animals,” said Steven M. Solomon, D.V.M., director of the FDA’s Center for Veterinary Medicine. “It

Genome 52

Genome Genomics Production Marketing 52

The Pharma Data

JANUARY 20, 2021

Nasdaq: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, including COVID-19, cancer and HPV-associated diseases, today announced the pricing of an underwritten public offering of 17,700,000 shares of its common stock at a public offering price of $8.50

DNA 40

DNA Containment Immune Response Sales 40

The Pharma Data

JANUARY 21, 2021

Session: Tumor Biology: Focus on EGFR Mutation, DNA Repair and Tumor Microenvironment Mini Oral Session Date and Time: January 31, 2021, 17:20 SGT (January 31, 2021 1:20 a.m. Spectrum Pharmaceuticals is a biopharmaceutical company focused on acquiring, developing, and commercializing novel and targeted oncology therapies.

Clinical Trials 52

Clinical Trials Clinical Trials Licensing Licensing 52

Delveinsight

JANUARY 4, 2021

2018), approximately 90% of infants got chronically infected, whereas the percent of adults developing Chronic Hepatitis B was less than 5%. The present Chronic Hepatitis B market also houses therapeutic vaccines including recombinant peptide-based vaccines, DNA-based vaccines, viral vector-based vaccines, and cell-based vaccines.

Marketing 52

Marketing Vaccination Vaccine DNA 52

pharmaphorum

JANUARY 14, 2021

service will allow secure access to real-world data from electronic health records (EHRs), DNA analysis and fitness wearables. However, the company’s head of strategic business development Parsi Parsinejad said that the system is differentiated from competitors by its focus on putting patients in control of their data.

Trials 52

Trials Clinical Trials Clinical Trials Pharma Companies 52

pharmaphorum

SEPTEMBER 8, 2022

Ben Hargreaves examines what advantages radiopharmaceuticals offer in the treatment of cancer and why there has been interest from big pharma in developing these types of therapies. This is why the recent surge in development for radiopharmaceuticals is drawing attention. Investment is flowing. Aktis has taken a different approach.

Manufacturing 104

Manufacturing Development Drugs Antibody 104

The Pharma Data

DECEMBER 14, 2020

”) platform to transform drug discovery and development, and identify patients who will benefit from its portfolio of targeted oncology therapeutics, announced today new scientific data that substantiates blood brain barrier permeability (BBB) for its drug candidate LP-184. . DALLAS , Dec. Lantern’s A.I.

Drugs 52

Drugs Genome Genomics DNA 52

The Pharma Data

DECEMBER 28, 2020

Amphastar’s newly approved synthetic peptide product was determined by the FDA to be bioequivalent and therapeutically equivalent to Eli Lilly’s Glucagon Emergency Kit for Low Blood Sugar, which has a recombinant DNA (rDNA)-origin. billion, three biosimilar products in development targeting products with a market size of approximately $13.0

Bioequivalency 52

Bioequivalency Production Sales Marketing 52

Advarra

MARCH 31, 2023

This trend came to the forefront during the COVID-19 pandemic, as the three most popular vaccines developed in response to the coronavirus contained engineered genetic materials in the form of mRNA or a genetically engineered virus. A key part of the IBC’s evaluation is assessing the risks posed by the engineered genetic materials.

Engineer 52

Engineer Genetics Clinical Research Research 52

The Pharma Data

DECEMBER 24, 2020

It penetrates through glass and clouds, damaging the cell’s DNA and aging skin.” ” About 20% of Americans will develop skin cancer by age 70, according to the Skin Cancer Foundation. It’s associated with skin types that contain different amounts of melanin.

Nurses 52

Nurses Dermatology DNA Containment 52